These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 17252597)
1. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Hoogsteen IJ; Marres HA; Bussink J; van der Kogel AJ; Kaanders JH Head Neck; 2007 Jun; 29(6):591-604. PubMed ID: 17252597 [TBL] [Abstract][Full Text] [Related]
2. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Vordermark D; Brown JM Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Koukourakis MI; Giatromanolaki A; Sivridis E; Pastorek J; Karapantzos I; Gatter KC; Harris AL; Int J Radiat Oncol Biol Phys; 2004 May; 59(1):67-71. PubMed ID: 15093900 [TBL] [Abstract][Full Text] [Related]
4. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Hoogsteen IJ; Marres HA; van der Kogel AJ; Kaanders JH Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):385-96. PubMed ID: 17433637 [TBL] [Abstract][Full Text] [Related]
5. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Bussink J; Kaanders JH; van der Kogel AJ Radiother Oncol; 2003 Apr; 67(1):3-15. PubMed ID: 12758235 [TBL] [Abstract][Full Text] [Related]
6. [The effect of the microenvironment of head and neck cancers on tumor progression]. Lukits J Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia in head and neck cancer: how much, how important? Janssen HL; Haustermans KM; Balm AJ; Begg AC Head Neck; 2005 Jul; 27(7):622-38. PubMed ID: 15952198 [TBL] [Abstract][Full Text] [Related]
8. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Wijffels KI; Marres HA; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH Oral Oncol; 2008 Apr; 44(4):335-44. PubMed ID: 17689286 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Hoogsteen IJ; Peeters WJ; Marres HA; Rijken PF; van den Hoogen FJ; van der Kogel AJ; Kaanders JH Radiother Oncol; 2005 Aug; 76(2):213-8. PubMed ID: 16112214 [TBL] [Abstract][Full Text] [Related]
10. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Silva P; Homer JJ; Slevin NJ; Musgrove BT; Sloan P; Price P; West CM Clin Otolaryngol; 2007 Oct; 32(5):337-45. PubMed ID: 17883552 [TBL] [Abstract][Full Text] [Related]
11. Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. Secades P; Rodrigo JP; Hermsen M; Alvarez C; Suarez C; Chiara MD Genes Chromosomes Cancer; 2009 May; 48(5):441-54. PubMed ID: 19235921 [TBL] [Abstract][Full Text] [Related]
12. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo. Sasaki Y; Kjellén E; Mineta H; Wennerberg J; Ekblad L Acta Oncol; 2009; 48(7):1062-9. PubMed ID: 19412811 [TBL] [Abstract][Full Text] [Related]
13. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Raleigh JA; Chou SC; Calkins-Adams DP; Ballenger CA; Novotny DB; Varia MA Clin Cancer Res; 2000 Mar; 6(3):855-62. PubMed ID: 10741707 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Dellas K; Bache M; Pigorsch SU; Taubert H; Kappler M; Holzapfel D; Zorn E; Holzhausen HJ; Haensgen G Strahlenther Onkol; 2008 Mar; 184(3):169-74. PubMed ID: 18330514 [TBL] [Abstract][Full Text] [Related]
15. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Mayer A; Höckel M; Vaupel P Strahlenther Onkol; 2006 Sep; 182(9):501-10. PubMed ID: 16944371 [TBL] [Abstract][Full Text] [Related]
16. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. Burstein DE; Nagi C; Kohtz DS; Lee L; Wang B Histopathology; 2006 May; 48(6):717-22. PubMed ID: 16681688 [TBL] [Abstract][Full Text] [Related]
17. Galectin-1: a link between tumor hypoxia and tumor immune privilege. Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933 [TBL] [Abstract][Full Text] [Related]
18. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Winter SC; Shah KA; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL Clin Cancer Res; 2005 Nov; 11(21):7614-20. PubMed ID: 16278379 [TBL] [Abstract][Full Text] [Related]
19. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia]. Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154 [TBL] [Abstract][Full Text] [Related]
20. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]